Antiretroviral drugs, used to prevent HIV transmission from mother to child, are now believed to cause genetic damage in infants. This damage, leading to an increased risk of developing cancer, makes it highly plausible these children may be diagnosed with the disease in mid and late adulthood.

Two new studies indicate there are cancer-causing effects of transplacental exposure to AZT, an antiretroviral drug. These effects -- like increased incidence of tumors and tumors with genetic changes -- have been demonstrated in mice and rats and seem to be cause for concern in humans too.

"The cumulative mutagenesis data suggest that infants exposed transplacentally to AZT may be at increased risk for cancer as they age," said one researcher, whose findings are published in Environment and Molecular Mutagenesis.

She doesn't have breast cancer. But she did have both breasts removed and reconstructed in January to ensure as much as she can that she will never develop the disease that has struck both her mother and father.

It's the dad connection that puts René Syler, former anchorwoman for The Early Show, at such risk for breast cancer. That and the dozens of microcalcifications -- these can indicate cancer -- that repeatedly revealed themselves on mammograms and the diagnosis of atypical ductal hyperplasia that increases the risk of cancer. And while cancer was never diagnosed for this woman who was sure the disease would one day catch up with her, Syler is no stranger to the world of biopsies. And her breasts -- misshapen, shriveled, collapsed, and scarred from so many surgical procedures -- were proof of her frequent rides on the breast cancer merry-go-round.

Now Syler's breasts are gone. And she is breathing a great big sigh of relief. She calls her new "girls" incredible. And she calls her new mood "good."

"I see now that the specter of breast cancer has been permeating my life," says Syler whose story appears in the April 2007 issue of The Oprah Magazine and whose book Good-Enough Mother will be published in April.

"I couldn't really live because I was always playing defense -- watching and waiting, wondering if this would be the year I'd be diagnosed."

2006 will forever be the year linking the decline in breast cancer cases to the decline in use of hormone replacement therapy (HRT). This was big news on the cancer front, and while some argue other forces helped drive the breast cancer drop, there is still much speculation that the use of HRT somehow increases the risk of developing the disease. Even so, it is predicted that Wyeth's sales of hormone replacement drugs will have reached more than $1 billion as of yesterday, the last day of 2006.

Even more interesting is the prediction by analysts that revenue from the pills -- used to treat symptoms of menopause -- will rise five percent annually for the next several years.

It seems the sales growth, despite the overall decline in the HRT market, is primarily due to increased demand from wholesalers and price increases too.

It's hard to tell what will happen to the world of HRT in the year 2007 -- will women embrace what is considered the best therapy around for menopausal issues? Will they abandon the controversial treatment altogether? Will they find variations of HRT that meet their needs while minimizing risk for disease? Only time will tell.